Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carbidopa
Drug ID BADD_D00359
Description Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier. Due to its activity, carbidopa is always administered concomitantly with [levodopa]. An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea.[T394] The first approved product by the FDA containing only carbidopa was developed by Amerigens Pharmaceuticals Ltd and approved on 2014.[L5110] On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination therapy developed by Mayne Pharma in 1992.[L5113]
Indications and Usage For treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), post-encephalitic parkinsonism
Marketing Status Prescription
ATC Code Not Available
DrugBank ID DB00190
KEGG ID D00558
MeSH ID D002230
PubChem ID 34359
TTD Drug ID D0P7JZ
NDC Product Code 67628-2001; 43386-980; 70771-1355; 63415-0024; 38779-0202; 51407-314; 42799-123; 65977-0131; 70600-018; 12780-4420; 52423-0901; 0006-0007; 62331-014; 62991-2848; 25010-711; 16714-067; 63629-1932; 43975-220; 59651-146; 58624-0621; 49452-1692; 70710-1221; 40032-980; 51504-0001
Synonyms Carbidopa | Methyldopahydrazine | MK-486 | MK 486 | MK486 | Lodosin | Lodosyn | MK-485 | MK 485 | MK485 | Carbidopa, (S)-Isomer | Carbidopa, (R)-Isomer
Chemical Information
Molecular Formula C10H14N2O4
CAS Registry Number 28860-95-9
SMILES CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Depression19.15.01.001--
Depression suicidal19.15.01.004--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry mouth07.06.01.002--
Duodenal ulcer07.04.02.002--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyskinesia17.01.02.006--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.004--
Dyspnoea22.02.01.004; 02.01.03.002--
Euphoric mood19.04.02.006--
Extrapyramidal disorder17.01.02.007--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gait disturbance08.01.02.002; 17.02.05.016--
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal pain07.01.05.005--
Glossodynia07.14.02.001--Not Available
Glucose urine13.13.02.016--Not Available
Haematocrit decreased13.01.05.001--Not Available
Blood urine present13.13.02.002--Not Available
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages